The autophagy-proteasome system represents the primary cellular machinery for clearing misfolded proteins and damaged organelles. In neurodegenerative diseases, both autophagy and proteasome function decline, leading to accumulation of toxic protein aggregates including [amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau), alpha-synuclein, and [TDP-43](/mechanisms/tdp-43-proteinopathy)[@tfeb2020][@autophagyproteasome2019]. This therapy proposes simultaneous activation of both pathways to achieve synergistic clearance of pathological protein species that neither pathway can handle alone[@alphasynuclein2018].
Pathway / Mechanism Diagram
graph TD
A["Nutrient Deprivation / Stress"] --> B["AMPK Activation"]
B --> C["ULK1 Complex Activation"]
A --> D["mTORC1 Inhibition"]
D --> C
C --> E["Phagophore Nucleation (VPS34/Beclin-1)"]
E --> F["LC3 Lipidation (LC3-II)"]
F --> G["Autophagosome Formation"]
G --> H["Cargo Recognition (p62/SQSTM1)"]
H --> I["Autophagosome-Lysosome Fusion"]
I --> J["Cargo Degradation"]
J --> K["Amino Acid Recycling"]
K --> L["Cell Survival"]
M["Autophagy Impairment in Aging"] --> N["Aggregate Accumulation"]
N --> O["Tau, Abeta, alpha-Synuclein Buildup"]
O --> P["Neurodegeneration"]
style L fill:#1b5e20,color:#e0e0e0
style P fill:#ef5350,color:#e0e0e0
style G fill:#006494,color:#e0e0e0
Rubric Scores
...
Overview
The autophagy-proteasome system represents the primary cellular machinery for clearing misfolded proteins and damaged organelles. In neurodegenerative diseases, both autophagy and proteasome function decline, leading to accumulation of toxic protein aggregates including [amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau), alpha-synuclein, and [TDP-43](/mechanisms/tdp-43-proteinopathy)[@tfeb2020][@autophagyproteasome2019]. This therapy proposes simultaneous activation of both pathways to achieve synergistic clearance of pathological protein species that neither pathway can handle alone[@alphasynuclein2018].
Pathway / Mechanism Diagram
Mermaid diagram (expand to render)
Rubric Scores
| Dimension | Score | Rationale | |-----------|-------|-----------| | Novelty | 7 | Dual activation concept is newer; components individually in trials | | Mechanistic Rationale | 9 | Strong scientific basis for combining autophagy + proteasome | | Addresses Root Cause | 9 | Targets protein aggregate clearance, fundamental problem | | Delivery Feasibility | 6 | Large molecules may have BBB issues; small molecule approaches exist | | Safety Plausibility | 7 | Autophagy modulation generally safe; proteasome excess needs monitoring | | Combinability | 9 | Can combine with many other mechanisms | | Biomarker Availability | 8 | LC3, p62, 20S proteasome activity measurable | | De-risking Path | 7 | Components in development; combination needs validation | | Multi-disease Potential | 9 | AD, PD, ALS, Huntington's - all protein aggregation diseases | | Patient Impact | 8 | High potential for disease modification |
Total: 73/100
Action Plan
Action Plan
Next Experiment: Test dual activation in iPSC [neurons](/entities/neurons) from AD/PD patients
Grant Target: NIH R01 (NIA) — "Dual proteostasis activation for neurodegeneration"
Industry Outreach: Contact companies developing TFEB activators and proteasome modulators
Clinical Protocol: Design biomarker-driven study in early disease patients
Actionable Next Steps
Lab Experiments
Dual activation validation: Test TFEB activator (rapamycin, trehalose)[@tfeb2020] + proteasome enhancer (NEDD8 pathway activator) combination in iPSC-derived neurons from AD and PD patients
Biomarker assay development: Validate LC3, p62, and 20S proteasome activity as pharmacodynamic markers in patient-derived neurons
Efficacy testing: Measure clearance of alpha-synuclein, tau, and TDP-43 aggregates in dual-treated neurons
Dose-optimization study: Determine synergistic dosing for TFEB activation and proteasome enhancement
Animal model testing: Evaluate dual activation in PS19 tauopathy mice and alpha-synuclein preformed fibril mice
Clinical Protocol Design
Patient selection: Enroll early-stage AD (Braak I-II) and PD (Hoehn & Yahr 1-2) patients with biomarker evidence of protein aggregation
Trial design: Randomized, placebo-controlled trial with biomarker primary endpoint (LC3, p62 in CSF)
Dose-finding: Establish maximum tolerated dose for combined TFEB activator + proteasome enhancer
Combination protocol: Plan add-on study with standard-of-care ([cholinesterase inhibitors](/entities/cholinesterase-inhibitors) for AD, dopamine agonists for PD)
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving Autophagy-Proteostasis Dual Activation discovered through SciDEX knowledge graph analysis: